Crowdonomics
This isn’t Republic Note’s most recent raise. Reg CF · Convertible Note · Aug 2024 (Closed) is more current.View latest round
Republic Note

Reg CF · Common Stock · Apr 2023

ClosedReached targetReg CFCommon Equity
via RepublicView campaign
Raised
$2M / $2M max
100% of ceiling · target hit day 3
Investors
2,450
$824.8 avg
Post-money valuation
$290M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$1.8M$917K$0
2.2K1.1K0
Apr 9, 2023 · openedApr 29, 2023 · last reading
Target ($360K) hit — Apr 12, 2023, day 3$1.0M raised — Apr 17, 2023Deadline Apr 30, 2023 — 1 days out

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via Republic; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2021–FY2022 · hover for source
$110K
−$11.7M
FY2021
$1.6M
$720K
FY2022
RevenueNet income
Metric
FY2021 audited
FY2022 audited
Income statement
Revenue
$109,520
$1,630,846
Cost of goods sold
$0
$0
Gross margin
100%
100%
Net income
-$11,670,080
$720,040
Taxes paid
$0
$0
Balance sheet
Cash
$3,486,798
$952,873
Accounts receivable
$13,236
$0
Total assets
$7,158,794
$13,626,121
Short-term debt
$316,937
$30,388,407
Long-term debt
$0
$0
Total liabilities
$316,937
$30,388,407
Other
Headcount
0
0

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Pre-money$288M
Post-money$290M
Price / share$0.36
Shares offered1,000,000

Offering details

Target$360,000
Max$2,020,811
Min investment$100
OpenedApr 9, 2023
DeadlineApr 30, 2023
ClosedApr 30, 2023
Days active21

Links & provenance

Source: Manual
0001794805-23-000007

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.